Thursday, February 2, 2023
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Pfizer and Biontech Expect to Have Omicron Variant Vaccine by March 2022

in Uncategorized
Us per capita carbon footprint looms large
Share on FacebookShare on Twitter

Pfizer and Biontech announced today that they expect to have a vaccine for the Omicron variant of Covid-19 by March 2022 if necessary to increase the level and duration of protection over it current vaccine.

The companies noted however that according to preliminary laboratory studies a third booster shot of its current vaccine neutralizes the new variant which has roiled the markets since its discovery in South Africa in November.

“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

Meanwhile early reports from South Africa suggest that the variant has had little effect on the mortality rate in Gauteng province, the epicenter of the Omicron outbreak, despite a significant rise in the number of infections. Fatalities kept trending downwards through at the beginning of December despite explosive growth of the case rate from below 5 per 100,000 in the beginning of October to above 30 per 100,000 in the December.

“A significant early finding in this analysis is the much shorter average length of stay of 2.8 days for SARS-CoV-2 positive patients admitted to the COVID wards over the last two weeks compared to an average length of stay of 8.5 days for the past 18 months,” noted the latest report from the South African Medical Research Council.

By Feike de Jong

Tags: 2022BioNTechMarchOnmicronPfizerVariant

Related Posts

Volvo group north america faces $130m civil penalty
News

Volvo Group North America faces $130M civil penalty

Why we can’t stop talking about greenwashing
Uncategorized

Why we can’t stop talking about greenwashing

Public ev charging in 2023
Uncategorized

Public EV Charging In 2023

More than 500 advertisers have paused spending on twitter
News

More than 500 advertisers have paused spending on Twitter

Sustainable smart cities for the future – automated parking
Environment

Sustainable smart cities for the future – Automated Parking

The 18 best bespoke tailors in the world: a comprehensive guide
Art & Culture

The 18 Best Bespoke Tailors in the World: A Comprehensive Guide

Bed bath & beyond may file bankruptcy
News

Bed Bath & Beyond may file bankruptcy

Commodities 2023 outlook: let’s not forget the weather, huh?
Opinion

Commodities 2023 Outlook: Let’s Not Forget the Weather, Huh?

Fewer single family homes being built
News

Fewer Single Family Homes Being Built

Elon musk polled twitter users. The majority said he should step down.
News

Elon Musk polled Twitter users. The majority said he should step down.

No Result
View All Result

Recent Posts

  • Tinder owner to lay off 8% of its staff as growth falters
  • Biden moves to slash U.S. credit card fees, app charges
  • New York City Votes To “Skip The Stuff” In Take-Out Orders
  • How to Test If Your Interview Process Is a Nightmare
  • The Next Era of Work Will Be About Skills, Not Pedigree

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials – stuart.james@ceo-na.com

    Editor-In-Chief – caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising – media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

     

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials –
    stuart.james@ceo-na.com

    Editor-In-Chief –

    caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising –
    media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In